Mar 01, 2021 5:00pm EST Medexus Achieves Record Revenue of $31.5 Million for the Third Quarter Fiscal 2021
Feb 23, 2021 8:51am EST Medexus Announces Closing of $32.5 Million Public Offering, Including Exercise in Full of Over-Allotment Option
Feb 16, 2021 4:43pm EST Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side
Feb 03, 2021 10:10am EST Medexus Announces Upsize to Previously Announced Bought Deal Public Offering
Feb 02, 2021 2:21pm EST Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell Transplantation, Treosulfan, in the United States
Jan 25, 2021 8:30am EST Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA®
